KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Exchange Rate Effect (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 14 years of Exchange Rate Effect data on record, last reported at $7000.0 in Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 111.67% year-over-year to $7000.0; the TTM value through Dec 2025 reached $26000.0, up 127.66%, while the annual FY2025 figure was $26000.0, 127.66% up from the prior year.
  • Exchange Rate Effect reached $7000.0 in Q4 2025 per ACAD's latest filing, down from $24000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $24000.0 in Q2 2025 and bottomed at -$60000.0 in Q4 2024.
  • Average Exchange Rate Effect over 5 years is -$4055.6, with a median of $1500.0 recorded in 2021.
  • Peak YoY movement for Exchange Rate Effect: plummeted 950.0% in 2024, then skyrocketed 700.0% in 2025.
  • A 5-year view of Exchange Rate Effect shows it stood at $1000.0 in 2021, then plummeted by 900.0% to -$8000.0 in 2022, then tumbled by 50.0% to -$12000.0 in 2023, then crashed by 400.0% to -$60000.0 in 2024, then surged by 111.67% to $7000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Exchange Rate Effect were $7000.0 in Q4 2025, $24000.0 in Q2 2025, and -$5000.0 in Q1 2025.